The European Commission has granted orphan drug designation to viltolarsen, a treatment for people with Duchenne muscular…
Grace Frank
Grace Frank has worked as an editor and reporter for leading American newspapers, including The New York Times, The International Herald Tribune and the Tampa Tribune. She has won numerous journalism awards, including recognition as the best education reporter in Florida (an annual honor given by the statewide teachers' union) and was nominated for a Pulitzer Prize for an investigative series into eye surgeries wrongly conducted outside a clinical trial. Grace holds a master's degree in international relations from the University of Chicago (attending on a full-tuition fellowship), and a bachelor's degree in political science from Rutgers University–Newark campus.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Grace Frank
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands,…
Expecting to award roughly $18 million in grants in 2020 to support research across neuromuscular diseases, the…
Gene therapies — after a tragedy kicked them back to the lab some two decades ago — are beginning to…
Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a…
The U.S. Food and Drug Administration has placed a clinical hold on a Phase 1/2 trial testing SGT-001, a dystrophin gene…
Just days after Emflaza (deflazacort) became the first corticosteroid approved in the U.S. to treat Duchenne muscular dystrophy (DMD) regardless…
Sarepta Therapeutics, Inc., announced that a U.S. Food and Drug Administration (FDA) advisory committee has been forced to postpone Friday’s…